Biotech M & A takes off as Sanofi and Celgene spend $20 billion
LONDON (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | France Health | Haemophilia | Health | Hemophilia